These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35840845)

  • 1. Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
    Lin SY; Chen YM; Chen WJ; Li CY; Ku CK; Chen CH; Chien LN
    Arch Osteoporos; 2022 Jul; 17(1):94. PubMed ID: 35840845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
    Morkos M; Mahrous P; Casagrande A; Go MT; Husni H; Hanna M; Goel M; Bedrose S; Li D; Baim S
    Endocr Pract; 2022 Oct; 28(10):1078-1085. PubMed ID: 35787466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The real-world adherence of the first-line anti-osteoporosis medications in Taiwan: Visualize the gap between reality and expectations.
    Lee CC; Fu SH; Chen HM; Lin JW; Hsu CC; Lin SC; Hwang JS; Yang RS; Wu CH; Wang CY
    J Formos Med Assoc; 2023; 122 Suppl 1():S55-S64. PubMed ID: 37302970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Persistence and Medication Switch Associated With Subsequent Fractures After Osteoporotic Fractures.
    Lin SY; Chen WJ; Ku CK; Chen YM; Chen CH; Chien LN
    J Clin Endocrinol Metab; 2023 Dec; 109(1):e200-e208. PubMed ID: 37526298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constraining in reimbursement criteria and the adherence to anti-osteoporosis medications (AOMs) in Taiwan: Urbanization makes the difference.
    Wang CY; Yang TH; Fu SH; Hwang JS; Chen HM; Lin JW; Hsu CC; Chang YF; Wu CH; Chan DC; Yang RS
    J Formos Med Assoc; 2023; 122 Suppl 1():S45-S54. PubMed ID: 37271714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
    Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Montero-Corominas D
    Arch Osteoporos; 2017 Dec; 12(1):39. PubMed ID: 28401495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
    Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
    Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
    Everts-Graber J; Bonel H; Lehmann D; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
    Osteoporos Int; 2023 Nov; 34(11):1961-1973. PubMed ID: 37493978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polypharmacy in Osteoporosis Treatment.
    McConnell M; Shieh A
    Clin Geriatr Med; 2022 Nov; 38(4):715-726. PubMed ID: 36210087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug utilization analysis of osteoporosis medications in seven European electronic health databases.
    Tan EH; Robinson DE; Jödicke AM; Mosseveld M; Bødkergaard K; Reyes C; Moayyeri A; Voss A; Marconi E; Lapi F; Reinold J; Verhamme KMC; Pedersen L; Braitmaier M; de Wilde M; Ruiz MF; Aragón M; Bosco-Levy P; Lassalle R; Prieto-Alhambra D; Sanchez-Santos MT
    Osteoporos Int; 2023 Oct; 34(10):1771-1781. PubMed ID: 37436441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.
    Singer AJ; Liu J; Yan H; Stad RK; Gandra SR; Yehoshua A
    Osteoporos Int; 2021 Dec; 32(12):2473-2484. PubMed ID: 34095966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of osteoporosis treatments in Germany.
    O'Kelly J; Bartsch R; Kossack N; Borchert J; Pignot M; Hadji P
    Arch Osteoporos; 2022 Aug; 17(1):119. PubMed ID: 36044096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eleven years secular trend of the initiation of anti-osteoporosis medications and subsequent fractures in Taiwan: From 2008 to 2018.
    Yang TH; Wang CY; Fu SH; Chan DC; Chen HM; Lin JW; Huang CF; Yang JJ; Wu CH; Hwang JS; Yang RS
    J Formos Med Assoc; 2023; 122 Suppl 1():S36-S44. PubMed ID: 37280138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis.
    Usui T; Funagoshi M; Seto K; Ide K; Tanaka S; Kawakami K
    Arch Osteoporos; 2018 May; 13(1):54. PubMed ID: 29725863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
    Albert SG; Reddy S
    Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study.
    Pedersen AB; Risbo N; Kafatos G; Neasham D; O'Kelly J; Ehrenstein V
    Arch Osteoporos; 2023 Jan; 18(1):19. PubMed ID: 36629929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.
    Petranova T; Boyanov M; Shinkov A; Petkova R; Intorcia M; Psachoulia E
    Arch Osteoporos; 2017 Dec; 13(1):1. PubMed ID: 29264666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.